Gemphire Therapeutics managed to get its IPO out in the dog days of summer. But it languished several weeks and then had to cut its pricing expectations.

A week after microcap Tokai saw its shares plummet after the failure of its key Phase III prostate cancer candidate galeterone, the biotech has unsurprisingly…

With a confidentiality agreement in place, Sanofi says it is ready to move quickly to wrap up its pursuit of Medivation.

Almost all of the biotech IPOs that have priced since the first quarter have broken issue, meaning that they are now trading below their offer price

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Biogen’s long-standing CEO Dr. George Scangos is to step down from the company in “the coming months” as the Big Biotech looks for a successor.

It’s been a torrid first half for Aegerion Pharmaceuticals that began the year with a 25% cut to its staff, but the biotech is swinging the ax again--this time…

Gene therapy player Audentes Therapeutics priced at the midpoint of its IPO range, raising $75 million, and then proceeded to move up about 10% in early…

Poxel has hit pause on its plan to file for an IPO on Nasdaq, opting instead to use its Euronext listing to generate €26.5 million to advance its Type 2…